Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer.
- Author:
Guo-chun LU
1
;
Fu FANG
;
De-chuan LI
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Chemotherapy, Adjuvant; Colorectal Neoplasms; drug therapy; pathology; surgery; Deoxycytidine; adverse effects; analogs & derivatives; therapeutic use; Disease-Free Survival; Female; Fluorouracil; administration & dosage; adverse effects; analogs & derivatives; therapeutic use; Follow-Up Studies; Foot Dermatoses; chemically induced; Hand Dermatoses; chemically induced; Humans; Leucovorin; administration & dosage; Male; Middle Aged; Neoplasm Staging; Neutropenia; chemically induced; Organoplatinum Compounds; administration & dosage; Retrospective Studies; Syndrome; Thrombocytopenia; chemically induced
- From: Chinese Journal of Oncology 2010;32(2):152-155
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy and toxicity of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin (5-Fu/LV) plus oxaliplatin (FOLFOX4) regimens as adjuvant chemotherapy for stage III colorectal cancer.
METHODSThe clinicopathological data of 118 patients with stage III colorectal cancer were studied retrospectively. The patients were assigned to receive either FOLFOX4 regimen (n = 76) or XELOX regimen (n = 42). 3-year disease-free survival (DFS) and adverse events as end points were compared between the two groups.
RESULTSThe number of patients that failed to finish 8 cycles was higher in FOLFOX4 group (28 vs. 8, P = 0.044). There was no significant difference for 3-year DFS and all grades adverse events between the two groups. However, the FOLFOX4 group showed more grade 3/4 neutropenia (31.6% vs. 14.3%, P = 0.039) and central venous catheter-associated complication (11.8% vs. 4.8%, P = 0.205), while XELOX showed more grade 3/4 thrombocytopenia (19.0% vs. 6.6%, P = 0.038) and hand-foot syndrome (11.9% vs. 1.3%, P = 0.012).
CONCLUSIONThe results of this analysis indicate that XELOX and FOLFOX4 regimens have very similar efficacy as an adjuvant chemotherapy for stage III colon cancer, but XELOX may be safer than FOLFOX4.
